Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance

BACKGROUND: In 2013, eculizumab was approved for treatment of the atypical hemolytic–uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Shuichi, Hidaka, Yoshihiko, Inoue, Norimitsu, Kaname, Shinya, Kato, Hideki, Matsumoto, Masanori, Miyakawa, Yoshitaka, Mizuno, Masashi, Okada, Hirokazu, Shimono, Akihiko, Matsuda, Takahisa, Maruyama, Shoichi, Fujimura, Yoshihiro, Nangaku, Masaomi, Kagami, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344608/
https://www.ncbi.nlm.nih.gov/pubmed/30039480
http://dx.doi.org/10.1007/s10157-018-1610-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344608/
https://www.ncbi.nlm.nih.gov/pubmed/30039480
http://dx.doi.org/10.1007/s10157-018-1610-2

Ejemplares similares